Sudden cardiac death: Difference between revisions

Jump to navigation Jump to search
No edit summary
(27 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
{| class="infobox" style="float:right;"
|-
| [[File:Siren.gif|30px|link= Cardiac arrest resident survival guide]]|| <br> || <br>
| [[Cardiac arrest resident survival guide|'''Resident'''<br>'''Survival'''<br>'''Guide''']]
|}
'''For patient information click [[Heart attack (patient information)|here]]'''
'''For patient information click [[Heart attack (patient information)|here]]'''
{{SI}}
{{Sudden cardiac death}}
{{CMG}}
{{CMG}}; '''Associate Editors-In-Chief:''' {{CZ}}; {{MUT}}
__NOTOC__
'''Associate Editor-In-Chief:''' {{CZ}}
 
'''Associate Editor-In-Chief:''' {{MUT}}
 
{{Editor Join }}
 
=Table of Contents=
==[[Sudden cardiac versus non-cardiac death]]==
==[[Sudden death differential diagnosis and causes|Causes and differential diagnosis]]==
==[[Sudden death definitions and diagnosis|Definitions and diagnosis]]
 
==Cardiac Arrest or VT/VF Occurring As A Complication of STEMI==
 
VT/VF and/or sudden death may occur early after the presentation of STEMI symptoms (<48 hours) and late after presentation (>48 hours)<ref name="pmid1951071">{{cite journal |author=Zehender M, Utzolino S, Furtwängler A, Kasper W, Meinertz T, Just H |title=Time course and interrelation of reperfusion-induced ST changes and ventricular arrhythmias in acute myocardial infarction |journal=Am. J. Cardiol. |volume=68 |issue=11 |pages=1138–42 |year=1991 |month=November |pmid=1951071 |doi= |url=}}</ref> <ref name="pmid1731450">{{cite journal |author=Gressin V, Louvard Y, Pezzano M, Lardoux H |title=Holter recording of ventricular arrhythmias during intravenous thrombolysis for acute myocardial infarction |journal=Am. J. Cardiol. |volume=69 |issue=3 |pages=152–9 |year=1992 |month=January |pmid=1731450 |doi= |url=}}</ref><ref name="pmid1883665">{{cite journal |author=Six AJ, Louwerenburg JH, Kingma JH, Robles de Medina EO, van Hemel NM |title=Predictive value of ventricular arrhythmias for patency of the infarct-related coronary artery after thrombolytic therapy |journal=Br Heart J |volume=66 |issue=2 |pages=143–6 |year=1991 |month=August |pmid=1883665 |pmc=1024606 |doi= |url=}}</ref><ref name="pmid3743145">{{cite journal |author=Buckingham TA, Devine JE, Redd RM, Kennedy HL |title=Reperfusion arrhythmias during coronary reperfusion therapy in man. Clinical and angiographic correlations |journal=Chest |volume=90 |issue=3 |pages=346–51 |year=1986 |month=September |pmid=3743145 |doi= |url=}}</ref><ref name="pmid8245327">{{cite journal |author=Berger PB, Ruocco NA, Ryan TJ, Frederick MM, Podrid PJ |title=Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial |journal=J. Am. Coll. Cardiol. |volume=22 |issue=7 |pages=1773–9 |year=1993 |month=December |pmid=8245327 |doi= |url=}}</ref><ref name="pmid9843464">{{cite journal |author=Newby KH, Thompson T, Stebbins A, Topol EJ, Califf RM, Natale A |title=Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators |journal=Circulation |volume=98 |issue=23 |pages=2567–73 |year=1998 |month=December |pmid=9843464 |doi= |url=}}</ref>.  The occurrence of both early and late VT/VF is associated with higher mortality. In a large contemporary analysis which included 5,745 high risk patients undergoing primary PCI in the APEX AMI trial, about 6% of patients developed VT/VF. the majority of the cases (64%) occurred during cardiac catheterization, and 90% of cases occurred withing 48 hours of presentation of STEMI symptoms. 90 day mortality was higher in those patients who sustained VT/VF (23.2% vs 3.6%, a multivariate hazard ratio of 3.63)<ref name="pmid19417195">{{cite journal |author=Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, Armstrong PW, Granger CB |title=Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention |journal=[[JAMA : the Journal of the American Medical Association]] |volume=301 |issue=17 |pages=1779–89 |year=2009 |month=May |pmid=19417195 |doi=10.1001/jama.2009.600 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=19417195 |issn=}}</ref>.  Mortality was higher among those patients with late VT/VF (33.3%) vs early VT/VF (17.2%).  It should also be noted that while many of the subsequent deaths in patients with VT/VF were due to sudden cardiac death, sudden cardiac death accounted for less than 50% of the mortality in VT/VF patients.  Although VT/VF was not associated with one year mortality in the Primary Angioplasty and Myocardial Infarction (PAMI) trials <ref>Mehta RH, Harjai KJ, Grines L, et al; Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes. JAmColl Cardiol. 2004;43(10):1765-1772.</ref>, this is likely due to the fact that the PAMI population was of lower risk and had a lower one year mortality (4.5% in PAMI vs 23.2% reported in the present study).
 
 
 
===Multivariate Predictors of Early VT/VF in the Setting of STEMI===
#Pre-PCI thrombolysis in MI (TIMI) flow grade 0 (HR, 2.94; 95% CI, 1.93-4.47)
#Inferior infarction (HR, 2.16;95%CI, 1.58-2.93)
#Total baseline ST deviation (HR, 1.39;95%CI, 1.19-1.63)
#Creatinine clearance (HR, 0.88; 95% CI, 0.83-0.94)
#Killip class greater than I (HR, 1.88;95%CI, 1.29-2.76)
#Baseline systolic blood pressure (HR, 0.92;95%CI, 0.87-0.98)
#Body weight (HR, 1.16; 95% CI, 1.04-1.29)
#baseline heart rate greater than 70/min (HR,1.10;95%CI, 1.01-1.20)
c index for the model = 0.75
 
===Multivariate Predictors of Late VT/VF in the setting of STEMI===
#Systolic blood pressure (HR, 0.83; 95% CI, 0.76-0.91)
#ST resolution less than 70% (HR, 3.17; 95% CI,1.60-6.28)
#Baseline heart rate greater than 70/min (HR, 1.20; 95% CI, 1.08-1.33)
#Total baseline ST deviation (HR, 1.43; 95% CI, 1.14-1.79)
#Post-PCI TIMI flow less than grade 3(HR, 2.09;95%CI, 1.24-3.52)
#Pre-PCI TIMI flow grade 0(HR, 2.12;95%CI, 1.20-3.75),
#Blockers less than 24 hours (HR, 0.52; 95% CI, 0.32-0.85)
c index for the model = 0.74
 
Multivariate modeling did demonstrate that about one-fifth of the variability in 90 day mortality was explained by VT/VF. It should be noted that many patients did not undergo left ventriculography in this study. When left ventricular ejection fraction was available and included in the multivariate model, it failed to be statistically significant. This is likely because it was co-linear with other variables such as Killip class, infarct location, TIMI flow and pulse.
 
===Clinical Implications===
Those patients with < TIMI grade 3 flow and < 70% ST resolution following PCI are at higher risk of VT/VF and should be monitored more carefully in an ICU or telemetry setting.
 
==VT/VF Complicating AMI (both STEMI and NSTEMI taken together)==
While the prior information focuses on STEMI, a study by Piccini et al of 9,000 patients focused on both STEMI as well as NSTEMI who underwent PCI within 24 hours of acute MI in the New York State Coronary Angioplasty Reporting System database <ref>Piccini JP, Berger JS, Brown DL. Early sustained ventricular arrhythmias complicating acute myocardial infarction. Am J Med. 2008;121(9):797-804. </ref>. 5.2% of patients sustained VT/VF and mortality was over 4 times higher among patients with VT/VF (16.3% vs 3.7%). Operator reported successful PCI was associated with a lower subsequent mortality associated with VT/VF. The following were identified as independent predictors of early VT/VF:
#Cardiogenic shock (OR, 4.10; 95%CI, 3.20-5.58)
#Heart failure (OR, 2.86;95% CI, 2.24-3.67)
#Chronic kidney disease (OR, 2.58; 95% CI, 1.27-5.23)
#Early presentation (6 hours from symptom onset; OR, 1.46; 95% CI, 1.18-1.81)
 
The following variables were found to be independently associated with a lower risk of VT/VF:
#History of hypertension (OR, 0.81; 95% CI, 0.65-1.00)
#Lleft circumflex as infarct artery (OR, 0.80; 95% CI, 0.65-0.99)
#Diabetes mellitus (OR,0.57; 95% CI, 0.42-0.78)
#Higher left ventricular ejection fraction (every 5% increment; OR, 0.93; 95% CI, 0.91-0.96)
 
==Cardiac Arrest: Treatment==
===Out of hospital arrest===
Most out-of-hospital cardiac arrests occur following a [[Myocardial infarction]] (heart attack), and present initially with a heart rhythm of [[Ventricular fibrillation]]. The patient is therefore likely to be responsive to [[defibrillation]], and this has become the focus of pre-hospital interventions. Several organisations promote the idea of a "[[chain of survival]]", of which defibrillation is a key step. The links are:
* '''Early recognition''' - If possible, recognition of illness before the patient develops a cardiac arrest will allow the rescuer to prevent its occurrence. Early recognition that a cardiac arrest has occurred is key to survival - for every minute a patient is in cardiac arrest, their chances of survival drop by roughly 10% <ref name="RCUK2005">Resuscitation Council UK (2005). ''Resuscitation Guidelines 2005'' London: Resuscitation Council UK.</ref>
* '''Early [[Cardiopulmonary resuscitation|CPR]]''' - This buys time by keeping vital organs perfused with oxygen whilst waiting for equipment and trained personnel to reverse the arrest. In particular, by keeping the brain supplied with oxygenated blood, chances of neurological damage are decreased.
* '''Early defibrillation''' - This is the only effective for [[Ventricular fibrillation]], and also has benefit in [[Ventricular tachycardia]]<ref name = "RCUK2005"/>. If defibrillation is delayed, then the rhythm is likely to degenerate into [[Asystole]], for which outcomes are markedly worse.
* '''Early post-resuscitation care''' - Treatment and rehabillitation in a hospital by specialist staff helps to prevent further complications, attempts to fully reverse the underlying cause, and promotes quality of life.
 
If one or more links in the chain are missing or delayed, then the chances of survival drop significantly. In particular, bystander CPR is an important indicator of survival: if it has not been carried out, then resuscitation is associated with very poor results. Paramedics in some jurisdictions are authorised to abandon resuscitation altogether if the early stages of the chain have not been carried out in a timely fashion prior to their arrival.
 
Because of this, considerable effort has been put into educating the public on the need for CPR. In addition, there is increasing use of public access defibrillation. This involves placing [[Automated external defibrillator]]s in public places, and training key staff in these areas how to use them. This allows defibrillation to take place prior to the arrival of emergency services, and has been shown to lead to increased chances of survival. In addition, it has been shown that those who suffer arrests in remote locations have worse outcomes following cardiac arrest <ref name="pmid15333549">{{cite journal |author=Lyon RM, Cobbe SM, Bradley JM, Grubb NR |title=Surviving out of hospital cardiac arrest at home: a postcode lottery? |journal=Emerg Med J |volume=21 |issue=5 |pages=619–24 |year=2004 |month=September |pmid=15333549 |pmc=1726412 |doi=10.1136/emj.2003.010363 |url=}}</ref>: these areas often have [[First responder]] schemes, whereby members of the community receive training in resuscitation and are given a defibrillator, and called by the emergency medical services in the case of a collapse in their local area.
 
===Cardiac Arrest: Hospital treatment===
Treatment within a hospital usually follows [[advanced life support]] protocols. Depending on the [[diagnosis]], various treatments are offered, ranging from [[defibrillation]] (for [[ventricular fibrillation]] or [[ventricular tachycardia]]) to [[surgery]] (for cardiac arrest which can be reversed by surgery - see causes of arrest, above) to [[medication]] (for [[asystole]] and [[pulseless electrical activity|PEA]]). All will include[[CPR]].
 
===Peri-arrest period===
The period (either before or after) surrounding a cardiac arrest is known as the '''peri-arrest period'''. During this period the patient is in a highly unstable condition and must be constantly monitored in order to halt the progression or repeat of a full cardiac arrest. The [[preventative treatment]] used during the peri-arrest period depends on the causes of the impending arrest and the likelihood such an event occurring.
 
==Cardiac Arrest: Prognosis==
The out-of-hospital cardiac arrest (OHCA) has a worse survival rate (2-8% at discharge and 8-22% on admission), than an in-hospital cardiac arrest (15% at discharge). The principal determining factor is the initially documented rhythm. Patients with VF/VT have 10-15 times more chance of surviving than those suffering from [[Pulseless electrical activity]] or [[Asystole]] (as they are sensitive to [[defibrillation]], whereas asystole and PEA are not).
 
Since mortality in case of OHCA is high, programs were developed to improve survival rate. A study by Bunch et al showed that, although mortality in case of ventricular fibrillation is high, rapid intervention with a [[defibrillator]] increases survival rate to that of patients that did not have a cardiac arrest.{{cite journal |author=Eisenberg MS, Mengert TJ |title=Cardiac resuscitation |journal=N. Engl. J. Med. |volume=344 |issue=17 |pages=1304–13 |year=2001 |month=April |pmid=11320390 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11320390&promo=ONFLNS19}}</ref><ref name="pmid12826637">{{cite journal |author=Bunch TJ, White RD, Gersh BJ, ''et al'' |title=Long-term outcomes of out-of-hospital cardiac arrest after successful early defibrillation |journal=N. Engl. J. Med. |volume=348 |issue=26 |pages=2626–33 |year=2003 |month=June |pmid=12826637 |doi=10.1056/NEJMoa023053 |url=}}</ref>
 
Survival is mostly related to the cause of the arrest (see above). In particular, patients who have suffered [[hypothermia]] have an increased survival rate, possibly because the cold protects the vital organs from the effects of tissue hypoxia. Survival rates following an arrest induced by toxins is very much dependent on identifying the toxin and administering an appropriate antidote. A patient who has suffered a [[myocardial infarction]] due to a [[blood clot]] in the [[Left coronary artery]] has a lower chance of survival as it cuts of the blood supply to most of the left ventricle (the chamber which must pump blood to the whole of the systemic circulation).
 
Cobbe et al (1996) conducted a study into survival rates from out of hospital cardiac arrest. 14.6% of those who had received resuscitation by ambulance staff survived as far as admission to an acute hospital ward. Of these, 59.3% died during that admission, half of these within the first 24 hours. 46.1% survived to hospital discharge (this is 6.75% of those who had been resuscitated by ambulance staff), however 97.5% suffered a mild to moderate neurological disability, and 2% suffered a major neurological disability. Of those who were successfully discharged from hospital, 70% were still alive 4 years after their discharge.<ref name="pmid15333549">{{cite journal |author=Lyon RM, Cobbe SM, Bradley JM, Grubb NR |title=Surviving out of hospital cardiac arrest at home: a postcode lottery? |journal=Emerg Med J |volume=21 |issue=5 |pages=619–24 |year=2004 |month=September |pmid=15333549 |pmc=1726412 |doi=10.1136/emj.2003.010363 |url=}}</ref><ref name="pmid8664715">{{cite journal |author=Cobbe SM, Dalziel K, Ford I, Marsden AK |title=Survival of 1476 patients initially resuscitated from out of hospital cardiac arrest |journal=BMJ |volume=312 |issue=7047 |pages=1633–7 |year=1996 |month=June |pmid=8664715 |pmc=2351362 |doi= |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=8664715}}</ref>
 
Ballew (1997) performed a review of 68 earlier studies into prognosis following in-hospital cardiac arrest. They found a survival to discharge rate of 14% (this roughly double the rate for out of hospital arrest found by Cobbe et al (see above)), although there was a wide range (0-28%).<ref name="pmid9167565">{{cite journal |author=Ballew KA |title=Cardiopulmonary resuscitation |journal=BMJ |volume=314 |issue=7092 |pages=1462–5 |year=1997 |month=May |pmid=9167565 |pmc=2126720 |doi= |url=http://bmj.com/cgi/pmidlookup?view=long&pmid=9167565}}</ref>
 
Several high profile organisations (such as [[St John Ambulance]] and the [[British Heart Foundation]]) have promoted the "Chain of Survival", which is made up of 4 links, as a way to maximise prognosis following arrest:
* Early Access - Identifying patients at risk of cardiac arrest early is the best way of improving prognosis, as it is often possible to prevent the arrest. Similarly, if the arrest is witnessed there is a much greater chance of survival, as treatment can begin straight away before tissue hypoxia sets in.
* Early [[CPR]] - CPR is unlikely to revive the patient, but it does buy some time by keeping a (limited) circulation going until it is possible to reverse the arrest, thereby increasing the chances of this reversal being successful, and minimising the risk of cerebral hypoxia (which can lead to neurological impairment following return of circulation).
* Early [[defibrillation]] - Patients who present with VF/VT can be defibrillated, and the earlier this happens the better, as VF/VT often degenerate into asystole (which is unshockable).
* Early [[hospital]] care - Many patients suffer further arrests within the first 24 hours of admission, so it is better that they are in hospital where their chances of survival are a little higher.
 
==Prevention==
With positive outcomes following cardiac arrest so unlikely, a great deal of effort has been spent in finding effective strategies to prevent cardiac arrest.
 
As noted above, one of the prime causes of cardiac arrest outside of hospital is [[ischemic heart disease]]. Vast resources have been put into trying to reduce cardiovascular risks across much of the developed world. In particular schemes have been put in place to promote a [[healthy diet]] and [[exercise]]. For people considered to be particularly at risk of heart disease, measures such as [[blood pressure]] control, prescription of [[cholesterol]] lowering medications, and other medico-therapeutic interventions, have been widely used. A [[magnesium deficiency (medicine)|magnesium deficiency]], or lower levels of [[magnesium]], can contribute to heart disease and a [[healthy diet]] that contains adequte [[magnesium]] may help prevent heart disease.<ref name="pmid15466951">{{cite journal |author=Rosanoff A, Seelig MS |title=Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals |journal=J Am Coll Nutr |volume=23 |issue=5 |pages=501S–505S |year=2004 |month=October |pmid=15466951 |doi= |url=http://www.jacn.org/cgi/pmidlookup?view=long&pmid=15466951}}</ref> [[Magnesium]] can be used to enhance long term treatment, so it may be effective in long term prevention.<p>
 
Patients in hospital are far less likely to have a cardiac arrest caused of primary cardiac origin, and hence present in Asystole or PEA, and have bleak outcomes. Extensive research has shown that patients in general wards often deteriorate for several hours or even days before a cardiac arrest occurs <ref name="pmid15325446">{{cite journal |author=Kause J, Smith G, Prytherch D, Parr M, Flabouris A, Hillman K |title=A comparison of antecedents to cardiac arrests, deaths and emergency intensive care admissions in Australia and New Zealand, and the United Kingdom--the ACADEMIA study |journal=Resuscitation |volume=62 |issue=3 |pages=275–82 |year=2004 |month=September |pmid=15325446 |doi=10.1016/j.resuscitation.2004.05.016 |url=}}</ref>. This has been attributed to a lack of knowledge and skill amongst ward based staff, in particular a failure to carry out measurement of the [[Respiratory rate]], which is often the major predictor of a deterioration and can often change up to 48 hours prior to a cardiac arrest. In response to this, many hospitals now have increased training for ward based staff. A number of "early warning" systems also exist which aim to quantify the risk which patients are at of deterioration based on their [[vital signs]] and thus provide a guide to staff. In addition, specialist staff are being utilised more effectively in order to augment the work already being done at ward level. These include:
* '''Crash teams''' (also known as '''Code teams''') - These are designated staff members who have particular expertise in resuscitation, who are called to the scene of all arrests within the hospital.
* '''Medical Emergency Teams''' - These teams respond to all emergencies, with the aim of treating the patient in the acute phase of their illness in order to prevent a cardiac arrest.
* '''Critical care outreach''' - As well as providing the services of the other two types of team, these teams are also responsible for educating non-specialist staff. In addition, they help to facilitate transfers between [[Intensive care unit|intensive care/high dependency units]] and the general hospital wards. This is particularly important, as many studies have shown that a significant percentage of patients discharged from critical care environments quickly deteriorate and are re-admitted - the outreach team offers support to ward staff to prevent this from happening.
 
==Implantable cardioverter defibrillators==
A technically based intervention to prevent further cardiac arrest episodes is the use of an '''[[implantable cardioverter-defibrillator]]''' (ICD).  This device is implanted in to the patient and can offer a 'pacemaker' effect to the heart as well as acting as an instant defibrillator in the event of arrhythmia.  A recent study  by Birnie et al at the University of Ottawa Heart Institute has demonstrated that ICDs are underused in both the United States and Canada.<ref name="pmid17606938">{{cite journal |author=Birnie DH, Sambell C, Johansen H, ''et al'' |title=Use of implantable cardioverter defibrillators in Canadian and US survivors of out-of-hospital cardiac arrest |journal=CMAJ |volume=177 |issue=1 |pages=41–6 |year=2007 |month=July |pmid=17606938 |pmc=1896034 |doi=10.1503/cmaj.060730 |url=}}</ref> An accompanying editorial by Simpson  explores some of the economic, geographic, social and political reasons for this.<ref name="pmid17606939">{{cite journal |author=Simpson CS |title=Implantable cardioverter defibrillators work--so why aren't we using them? |journal=CMAJ |volume=177 |issue=1 |pages=49–51 |year=2007 |month=July |pmid=17606939 |pmc=1896028 |doi=10.1503/cmaj.070470 |url=}}</ref>
 
==Prevention of Sudden Cardiac Death==
===ACC / AHA Guidelines- Recommendations for Implantable Cardioverter Defibrillators (DO NOT EDIT) <ref name="pmid18483207">{{cite journal |author=Epstein AE, DiMarco JP, Ellenbogen KA, ''et al'' |title=ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons |journal=Circulation |volume=117 |issue=21 |pages=e350-408 |year=2008 |month=May |pmid=18483207 |doi:10.1161/CIRCUALTIONAHA.108.189742 |url=}}</ref>===
{{cquote| 
===Class I===
 
1. [[ICD therapy]] is indicated in patients who are survivors of [[cardiac arrest]] due to [[VF]] or hemodynamically unstable sustained [[VT]] after evaluation to define the cause of the event and to exclude any completely reversible causes. (Level of Evidence: A)
 
2. [[ICD therapy]] is indicated in patients with structural [[heart disease]] and spontaneous sustained [[VT]], whether hemodynamically stable or unstable. (Level of Evidence: B)
 
3. [[ICD therapy]] is indicated in patients with [[syncope]] of undetermined origin with clinically relevant, hemodynamically significant sustained [[VT]] or [[VF]] induced at electrophysiological study. (Level of Evidence: B)
 
4. [[ICD therapy]] is indicated in patients with [[LVEF]] less than 35% due to prior [[MI]] who are at least 40 days post-MI and are in NYHA functional Class II or III. (Level of Evidence: A)
 
5. [[ICD therapy]] is indicated in patients with [[nonischemic DCM]] who have an [[LVEF]] less than or equal to 35% and who are in NYHA functional Class II or III. (Level of Evidence: B)
 
6. [[ICD therapy]] is indicated in patients with [[LV dysfunction]] due to prior [[MI]] who are at least 40 days post-MI, have an [[LVEF]] less than 30%, and are in NYHA functional Class I. (Level of Evidence: A)
 
7. [[ICD therapy]] is indicated in patients with [[nonsustained VT]] due to prior [[MI]], [[LVEF]] less than 40%, and [[inducible VF]] or [[sustained VT]] at electrophysiological study. (Level of Evidence: B)
 
===Class IIa===
 
1. [[ICD implantation]] is reasonable for patients with unexplained [[syncope]], significant [[LV dysfunction]], and [[nonischemic DCM]]. (Level of Evidence: C)
 
2. [[ICD implantation]] is reasonable for patients with [[sustained VT]] and normal or near-normal [[ventricular function]]. (Level of Evidence: C)
 
3. [[ICD implantation]] is reasonable for patients with [[HCM]] who have 1 or more major{dagger} risk factors for [[SCD]]. (Level of Evidence: C)
 
4. [[ICD implantation]] is reasonable for the prevention of [[SCD]] in patients with [[ARVD/C]] who have 1 or more risk factors for [[SCD]]. (Level of Evidence: C)
 
5. [[ICD implantation]] is reasonable to reduce [[SCD]] in patients with [[long-QT syndrome]] who are experiencing [[syncope]] and/or [[VT]] while receiving [[beta blockers]]. (Level of Evidence: B)
 
6. [[ICD implantation]] is reasonable for non hospitalized patients awaiting [[transplant]]ation. (Level of Evidence: C)
 
7. [[ICD implantation]] is reasonable for patients with [[Brugada syndrome]] who have had [[syncope]]. (Level of Evidence: C)
 
8. [[ICD implantation]] is reasonable for patients with [[Brugada syndrome]] who have documented [[VT]] that has not resulted in [[cardiac arrest]]. (Level of Evidence: C)
 
9. [[ICD implantation]] is reasonable for patients with [[catecholaminergic polymorphic VT]] who have syncope and/or documented sustained [[VT]] while receiving [[beta blockers]]. (Level of Evidence: C)
 
10. [[ICD implantation]] is reasonable for patients with [[cardiac sarcoidosis]], [[giant cell myocarditis]], or [[Chagas disease]]. (Level of Evidence: C)
 
===Class IIb===
 
1. [[ICD therapy]] may be considered in patients with nonischemic [[heart disease]] who have an [[LVEF]] of less than or equal to 35% and who are in NYHA functional Class I. (Level of Evidence: C)
 
2. [[ICD therapy]] may be considered for patients with [[long-QT syndrome]] and risk factors for [[SCD]]. (Level of Evidence: B)
 
3. [[ICD therapy]] may be considered in patients with [[syncope]] and advanced structural heart disease in whom thorough invasive and noninvasive investigations have failed to define a cause. (Level of Evidence: C)
 
4. [[ICD therapy]] may be considered in patients with a [[familial cardiomyopathy]] associated with sudden death. (Level of Evidence: C)
 
5. [[ICD therapy]] may be considered in patients with [[LV]] noncompaction. (Level of Evidence: C)
 
===Class III===
 
1. [[ICD therapy]] is not indicated for patients who do not have a reasonable expectation of survival with an acceptable functional status for at least 1 year, even if they meet [[ICD implantation]] criteria specified in the Class I, IIa, and IIb recommendations above. (Level of Evidence: C)
 
2. [[ICD therapy]] is not indicated for patients with incessant [[VT]] or [[VF]]. (Level of Evidence: C)
 
3. [[ICD therapy]] is not indicated in patients with significant [[psychiatric illness]]es that may be aggravated by device implantation or that may preclude systematic follow-up. (Level of Evidence: C)
 
4. [[ICD therapy]] is not indicated for NYHA Class IV patients with [[drug-refractory congestive heart failure]] who are not candidates for [[cardiac transplantation]] or [[CRT-D]]. (Level of Evidence: C)
 
5. [[ICD therapy]] is not indicated for [[syncope]] of undetermined cause in a patient without [[inducible ventricular tachyarrhythmias]] and without structural [[heart disease]]. (Level of Evidence: C)
 
6. [[ICD therapy]] is not indicated when [[VF]] or [[VT]] is amenable to surgical or catheter ablation (e.g., [[atrial arrhythmias]] associated with the [[Wolff-Parkinson-White syndrome]], [[RV]] or [[LV]] [[outflow tract VT]], [[idiopathic VT]], or [[fascicular VT]] in the absence of structural [[heart disease]]). (Level of Evidence: C)
 
7. [[ICD therapy]] is not indicated for patients with [[ventricular tachyarrhythmias]] due to a completely reversible disorder in the absence of structural [[heart disease]] (e.g., [[electrolyte imbalance]], [[drugs]], or [[trauma]]). (Level of Evidence: B)}}


===ACC / AHA Guidelines- Recommendations for Implantable Cardioverter-Defibrillators in Pediatric Patients and Patients With Congenital Heart Disease (DO NOT EDIT) <ref name="pmid18483207">{{cite journal |author=Epstein AE, DiMarco JP, Ellenbogen KA, ''et al'' |title=ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons |journal=Circulation |volume=117 |issue=21 |pages=e350-408 |year=2008 |month=May |pmid=18483207 |doi:10.1161/CIRCUALTIONAHA.108.189742 |url=}}</ref>===
==[[Sudden cardiac versus non-cardiac death|Sudden Cardiac versus Non-Cardiac Death]]==
{{cquote|
==[[Sudden cardiac death causes|Causes]]==
===Class I===
==[[Sudden cardiac death definitions and diagnosis|Definitions and Diagnosis]]==
==[[Sudden cardiac death risk factors|Risk Factors]]==


1. [[ICD implantation]] is indicated in the survivor of [[cardiac arrest]] after evaluation to define the cause of the event and to exclude any reversible causes. (Level of Evidence: B)
==[[Sudden cardiac death prognosis|Prognosis]]==
==[[Sudden cardiac death urgent treatment|Urgent Treatment]]==
==[[Sudden cardiac death prevention|Post Arrest Care and Prevention]]==
==[[Sudden cardiac death ethical issues|Ethical Issues]]==


2. [[ICD implantation]] is indicated for patients with [[symptomatic sustained VT]] in association with [[congenital heart disease]] who have undergone hemodynamic and electrophysiological evaluation. [[Catheter ablation]] or surgical repair may offer possible alternatives in carefully selected patients. (Level of Evidence: C)
==Related Chapters==
 
===Class IIa===
 
1. [[ICD implantation]] is reasonable for patients with [[congenital heart disease]] with [[recurrent syncope]] of undetermined origin in the presence of either [[ventricular dysfunction]] or [[inducible ventricular arrhythmia]]s at electrophysiological study. (Level of Evidence: B)
 
===Class IIb===
 
1. [[ICD implantation]] may be considered for patients with [[recurrent syncope]] associated with complex [[congenital heart disease]] and [[advanced systemic ventricular dysfunction]] when thorough invasive and noninvasive investigations have failed to define a cause. (Level of Evidence: C)
 
===Class III===
 
1. All Class III recommendations found in Section 3, "Indications for Implantable Cardioverter-Defibrillator Therapy," apply to pediatric patients and patients with [[congenital heart disease]], and [[ICD implantation]] is not indicated in these patient populations. (Level of Evidence: C) }}
 
==Cardiac Arrest: Ethical Issues==
[[Cardiopulmonary resuscitation]] and [[advanced cardiac life support]] are not always in a person's best interest. This is particularly true in the case of terminal illnesses when resuscitation will not alter the outcome of the disease. Properly performed CPR often fractures the [[rib]] cage, especially in older patients or those suffering from [[osteoporosis]]. [[Defibrillation]], especially repeated several times as called for by [[advanced cardiac life support|ACLS]] protocols, may also cause electrical burns.
 
Some people with a [[terminal illness]] choose to avoid such measures and die peacefully. People with views on the treatment they wish to receive in the event of a cardiac arrest should discuss these views with both their [[physician|doctor]] and with their family. A patient may ask their doctor to record a [[do not resuscitate]] (DNR) order in the medical record. Alternatively, in many jurisdictions, a person may formally state their wishes in an advance directive or [[advance health directive]].
 
 
==See also==
* [[Asystole]]
* [[Asystole]]
* [[Clinical death]]
* [[Clinical death]]
Line 211: Line 27:
* [[Near-death experience]]
* [[Near-death experience]]
* [[Ventricular fibrillation]]
* [[Ventricular fibrillation]]
 
* [[Anoxic brain injury]]
==References==
{{clr}}
{{reflist|2}}
 
==Additional resources==
    Normal  0              false  false  false      EN-US  X-NONE  X-NONE                                                    MicrosoftInternetExplorer4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    * [http://www.sca-aware.org Sudden Cardiac Arrest Foundation]
 
{{Electrocardiography}}
{{SIB}}


[[Category:Cardiology]]
[[Category:Cardiology]]
Line 229: Line 38:
[[fi:Äkkikuolema]]
[[fi:Äkkikuolema]]
[[tr:Ani kardiyak ölüm]]
[[tr:Ani kardiyak ölüm]]
test


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 03:07, 17 January 2014



Resident
Survival
Guide

For patient information click here

Sudden cardiac death Microchapters

Home

Patient Information

Sudden Cardiac versus Non-Cardiac Death

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Definitions and Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Urgent Treatment

Post Arrest Care and Prevention

Ethical Issues

Sudden cardiac death On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sudden cardiac death

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sudden cardiac death

CDC on Sudden cardiac death

Sudden cardiac death in the news

Blogs on Sudden cardiac death

Directions to Hospitals Treating Sudden cardiac death

Risk calculators and risk factors for Sudden cardiac death

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; M.Umer Tariq [3]

Sudden Cardiac versus Non-Cardiac Death

Causes

Definitions and Diagnosis

Risk Factors

Prognosis

Urgent Treatment

Post Arrest Care and Prevention

Ethical Issues

Related Chapters

fi:Äkkikuolema


Template:WikiDoc Sources